Epigenetic based synthetic lethal strategies in human cancers
Abstract Over the past decades, it is recognized that loss of DNA damage repair (DDR) pathways is an early and frequent event in tumorigenesis, occurring in 40-50% of many cancer types. The basis of synthetic lethality in cancer therapy is DDR deficient cancers dependent on backup DNA repair pathway...
Main Authors: | Aiai Gao, Mingzhou Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40364-020-00224-1 |
Similar Items
-
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
by: Win Topatana, et al.
Published: (2020-09-01) -
In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
by: Jian Li, et al.
Published: (2016-02-01) -
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
by: Monika Toma, et al.
Published: (2019-10-01) -
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
by: Jaromir Hunia, et al.
Published: (2022-12-01) -
Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use
by: Rachel Abbotts, et al.
Published: (2022-05-01)